Tregalizumab

Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies[1][2][3].

Product Specifications

CAS Number

[1207446-68-1]

Product Name Alternative

BT-061

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tregalizumab.html

Purity

98.97

Solubility

10 mM in DMSO

Smiles

[Tregalizumab]

Molecular Weight

(147.42 kDa)

References & Citations

[1]König M, et al. Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol. 2016 Jan 25;7:11. |[2]Vogel S, et al. Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64 (+) cells. Sci Rep. 2015 Dec 16;5:18308. |[3]Helling B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015 Apr;93 (4) :396-405.